Wedbush Brokers Raise Earnings Estimates for Replimune Group

Replimune Group, Inc. (NASDAQ:REPL) – Research analysts at Wedbush increased their Q3 2025 earnings estimates for shares of Replimune Group in a note issued to investors on Tuesday, January 21st. Wedbush analyst R. Driscoll now expects that the company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.68). The consensus estimate for Replimune Group’s current full-year earnings is ($2.91) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.91) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.78) EPS.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07.

A number of other analysts have also weighed in on REPL. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright increased their price objective on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets boosted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $19.14.

Replimune Group Trading Up 9.9 %

REPL stock opened at $13.02 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The firm’s 50-day moving average price is $12.18 and its two-hundred day moving average price is $11.28.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. SG Americas Securities LLC grew its holdings in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock worth $318,000 after purchasing an additional 3,374 shares during the period. JPMorgan Chase & Co. increased its position in shares of Replimune Group by 3.3% during the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock valued at $2,733,000 after acquiring an additional 8,074 shares during the last quarter. Barclays PLC raised its stake in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after acquiring an additional 98,791 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.